Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...
Anti-tumor activity of BH-30643, a novel macrocyclic kinase inhibitor, in EGFR-mutant lung cancer models. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results